May 15, 2021
Treating patients with atherosclerotic cardiovascular disease (ASCVD) with low-dose aspirin is just as effective as using the 325-mg dose for the prevention of major cardiovascular events, and both doses are associated with a very low rate of bleeding, according to findings from the open-label, pragmatic ADAPTABLE trial.
The results, presented as a late-breaking clinical trial during the American College of Cardiology 2021 Scientific Session and published simultaneously in the
New England Journal of Medicine, suggest equivalence between the two doses and should help inform clinical practice in the United States, where there is some uncertainty about the right aspirin dose for secondary prevention, say investigators.